Physician profile
Roger S Gammon
NPI 1366435810
$9,070.66
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $8,035 · 2021: $298.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idev Technologies, INC. | $7,864.62 | 2020 | |
| Biotronik INC. | $308.40 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $308.06 | 2019 | |
| Abbott Laboratories | $117.60 | 2021 | |
| Boston Scientific Corporation | $113.30 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $83.42 | 2019-2020 | |
| Shockwave Medical, INC | $63.85 | 2019-2021 | |
| Abiomed | $60.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.21 | 2020-2021 | |
| Medtronic Vascular, INC. | $24.46 | 2019 | |
| Biocompatibles, INC. | $16.39 | 2019 | |
| Chiesi USA, INC. | $14.85 | 2021 | |
| Pfizer INC. | $11.36 | 2019 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Gammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.